Cargando…
Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab
BACKGROUND: Trastuzumab (TRA) shows significant efficacy in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). While TRA can help treat HER2-positive breast cancer, TRA resistance is a key clinical challenge. Nestin reportedly regulates the cellular redox hom...
Autores principales: | Wei, Yi-Chou, Zhu, Jiang-Yi, Wu, Jing, Yu, Shan, Li, Wei, Zhu, Meng-Xuan, Liu, Tian-Shu, Cui, Yue-Hong, Li, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502550/ https://www.ncbi.nlm.nih.gov/pubmed/37720426 http://dx.doi.org/10.21037/jgo-22-1048 |
Ejemplares similares
-
Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance
por: Zhang, Yan, et al.
Publicado: (2016) -
Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells
por: Wang, Wenbin, et al.
Publicado: (2021) -
Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines
por: Veselska, Renata, et al.
Publicado: (2008) -
A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer
por: Ma, Tingting, et al.
Publicado: (2022) -
Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
por: Wu, Jianhua, et al.
Publicado: (2021)